TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502) Stock Could Be 18.9% Undervalued After Phase 3 Drug Updates
Takeda Pharmaceutical (TSE:4502) is back in focus after fresh Phase 3 data on its narcolepsy candidate oveporexton and psoriasis drug zasocitinib, sharpening attention on how this late stage pipeline might influence the stock.
See our latest analysis for Takeda Pharmaceutical.
Takedas share price is ¥4,975, with the stock easing over the past three months as the 90 day share price return fell 12.15%, even though the 1 year total shareholder return is 20.88%. This suggests longer term holders...